Abstract: An organic material consisting of a ?-conjugated molecule which is in a liquid form at ambient temperature and use thereof are provided. The ambient temperature liquid-form organic material according to the present invention consists of a ?-conjugated molecule having 2 or more side chains, the 2 or more side chains are same or different side chains selected from the group consisting of a branched alkyl chain, an alkyl chain having a polymerization site at a terminal, an oligosiloxane chain, a fluorocarbon chain, an oligoethylene glycol chain and derivatives thereof, and each of the 2 or more side chains is bound directly or via a substituent to the ?-conjugated molecule.

Abstract: The present invention provides compounds and methods of using of the compounds as anti-infective and anthelminitc agents. In a preferred embodiment, the present invention provides the following compound of Formula III: wherein: R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is OH or CH(2n+1)O, wherein n is 1-10; R2 is OH or CH(2n+1)O, where n is 1-10; W is alkyl, phenyl, halophenyl, pyridyl, piperidyl, or a substituted or unsubstituted aryl group, including unsubstituted and substituted aromatic heterocycles; and L is an optional linker or linking group selected from O, S, NH, CF2, or CH2, and x=0 or 1, i.e., if x=0, no linking group is present and when x=0, W is not phenyl.

Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.

Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.

Abstract: A compound represented by the formula (1) is provided. In the formula (1), for example, R1 and R2 are alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 2 to 10 carbons; the ring A and the ring B are 1,4-cyclohexylene or 1,4-phenylene; Z1 and Z2 are a single bond and Z3 is —CH2O— or —OCH2—; Y1 and Y2 are halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2 or —OCH2F; and m and n is 0, 1 or 2, p is 1 or 2, and the sum of m, n and p is 1, 2 or 3.

Abstract: A fluorine-containing aromatic compound represented by a formula: Q(W—ArF(Z)k)n is provided. The Q is an n-valent aromatic hydrocarbon group obtained by removing n-pieces of hydrogen atoms from a monocyclic structure, a polycyclic assembly structure, or a condensed polycyclic structure of one or more benzene rings or heterocycles. The W is a hydrocarbon group having an unsaturated bond of which carbon number is two. The ArF is a fluorine-containing aromatic hydrocarbon group. The Z is a monovalent organic group selected from —R, —OR, —Rf, or the like. The “R” is an alkyl group of which carbon number is one to 12, the “Rf” is a fluorine-substituted alkyl group of which carbon number is one to 12.

Abstract: An object of the present invention is to provide (i) a novel non-crystalline form of 9,9-bis(4-(2-hydroxyethoxy) phenyl) fluorene, which non-crystalline form maintains quality at a certain level, and is excellent as a polymer material, and (ii) a method of preparing the non-crystalline form. According to the present invention, molten 9,9-bis(4-(2-hydroxyethoxy) phenyl) fluorene in a liquid form is cooled and therefore is solidified. With the method, it is possible to provide a novel non-crystalline form of 9,9-bis(4-(2-hydroxyethoxy) phenyl) fluorene which has a small risk that powder dust of 9,9-bis(4-(2-hydroxyethoxy) phenyl) fluorine might cause explosion or a health problem. Further, the non-crystalline form of 9,9-bis(4-(2-hydroxyethoxy) phenyl) fluorene can be adjusted arbitrarily in particle diameter by, for example, pulverizing the non-crystalline form in accordance with equipment or usage.

Abstract: An improved process and method for the formation of stable intermediate cyclophanes. Embodiments describe a general method for the production of substituted and unsubstituted cyclophanes. The components include a pyrolysis reaction tube that may be electrically heated into which a flowing stream of nitrous oxide with xylene vapor in an optional inert carrier gas at atmospheric pressure. The exit gas is condensed resulting in the deposition of [2,2?]paracyclophane. Additionally a process and method whereby the reactive intermediates of the reaction described above can be directly deposited and polymerized at atmospheric pressures or thereabout is disclosed.

Abstract: Novel aromatic ether-containing monomers are described along with processes for their preparation and their polymerization into corresponding aromatic ether-containing polyfluorenes. These polyfluorenes exhibited stable blue-emission and therefore have application in polymer light-emitting devices.

Abstract: In a process for producing high molecular weight polyethylene, ethylene is contacted with a slurry of a catalyst composition comprising a Group 4 metal complex of a phenolate ether ligand under polymerization conditions comprising a temperature of about 20° C. to less than 90° C. and a pressure of about 4 bar to about 40 bar.

Abstract: A heterocyclic compound represented by one of Formulae 1-4 below and an organic light-emitting device including an organic layer that includes the heterocyclic compound. The heterocyclic compounds have excellent light-emitting characteristics and excellent electron transporting characteristics, and thus may be used as electron injecting materials or electron transporting materials suitable for all-color fluorescent and phosphorescent devices, such as red, green, blue, and white fluorescent and phosphorescent devices. In particular, the heterocyclic compounds are efficiently used as light-emitting materials of green, blue, and while fluorescent devices. By using the heterocyclic compounds, organic light-emitting devices having high efficiency, low driving voltage, high brightness, and long lifespan may be prepared.

Abstract: OLED compounds of the general structure: B—S-A-S—B in which rod-like nuclei A includes a condensed aromatic ring structure in turn having fluorene ring structures condensed with at least one additional fluorene ring structures wherein the fluorene ring systems provided by the condensed aromatic structure are substituted at the 9-position, and in which the 9-positions of the fluorenes are not susceptible to oxidation.

Abstract: An organic compound contains indacenodiperylene as the basic skeleton.

Abstract: Drilling fluids comprising graphenes and nanoplatelet additives and methods for production thereof are disclosed. Graphene includes graphite oxide, graphene oxide, chemically-converted graphene, and functionalized chemically-converted graphene. Derivatized graphenes and methods for production thereof are disclosed. The derivatized graphenes are prepared from a chemically-converted graphene through derivatization with a plurality of functional groups. Derivatization can be accomplished, for example, by reaction of a chemically-converted graphene with a diazonium species. Methods for preparation of graphite oxide are also disclosed.

Abstract: Enantioenriched compositions of liphagal and its derivatives and precursors include more than 50 mol % of a first enantiomer based on the total amount of a first and a second enantiomer. A method of making an enantioenriched composition includes catalytic enantioselective alkylation, ring expansion, and intramolecular aryne cyclization.

Abstract: This invention relates to a chemistry branch, particularly to the field of compounds' organic synthesis that belongs to the aromatic bicyclic or naphthalene category, used in the detection of amyloid sheets. These new naphthalene derivatives have a general formula: Wherein R represents mutually independent groups. In I: R1:-alkylenyl-C(O)NH-alkylenyl-R3, -alkylenyl-C(O)O—R4, R3:—COOH, —OH, —SH, —NH2, -alkyl-NH-alkyl-N-dithiocarbamate alkaline earth metal salts, R4: H, succinimidyl group, R2: —H,-alkyl. In II: R1: -alkyl, -alkylenyl-halide-alkylenyl-hydroxyl-alkylenyl-O-aryl, —O-alkylsulfonate alkylenyl, R2: -halide-alkylenyl-O-aryl, -alkylenyl-O-alkylsulfonate, -alkylenyl-halide-, —CH(O), —HC?C(CN)2, —HC?CHNO2, -alkylenyl-NH2, -alkylenyl-NH-alkyl, -alkylenyl-alkyl-N-dithiocarbamate alkaline salts. The terms “alkyl” and “alkylenyl” refer to linear or branched aliphatic chains, preferably from 1 to 4 carbon atoms and the term halide to fluorine, bromine or iodine.

Abstract: The present invention relates to Aromatic ring substituted dianthracene compounds and pertains to the field of synthesis of organic light-emitting materials. Aromatic ring substituted dianthracene compounds in the formula (I) present high glass transition temperature and solution efficiency, which can be used as effective blue-light emitting host materials.

Abstract: The invention relates to a new process for the synthesis of high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.

Abstract: A liquid crystal compound having a high stability to heat, light or the like, a high clearing point, a low minimum temperature of a liquid crystal phase, a small viscosity, a suitable optical anisotropy, a large negative dielectric anisotropy, a suitable elastic constant and an excellent compatibility with other liquid crystal compounds, and a liquid crystal composition including this compound, and a liquid crystal display device containing this composition. A compound represented by formula (1-1). In the formula, for example, R1 and R2 are alkyl having 1 to 10 carbons or alkoxy having 1 to 9 carbons; ring A1 and ring A2 are 1,4-cyclohexylene, 1,4-phenylene or 2,3-difluoro-1,4-phenylene; Z1 and Z2 are a single bond or —(CH2)2—; >W1—W2— and >W4—W3— are >CH—CH2— or >C?CH—; and m and n are 0, 1 or 2, and the sum of m and n is 1 or 2.

Abstract: Disclosed are: a cyclic compound which has high solubility in a safe solvent, is highly sensitive, enables the formation of a resist pattern having a good shape, and rarely causes resist pattern collapse; a process for producing the cyclic compound; a radiation-sensitive composition containing the cyclic compound; and a resist pattern formation method using the composition. Specifically disclosed are: a cyclic compound having a specific structure; a process for producing the cyclic compound; a radiation-sensitive composition containing the compound; and a resist pattern formation method using the composition.

Abstract: An organic compound is an acenaphtho[1,2-k]benzo[e]acephenanthrene derivative represented by general formula (1): where R1 and R2 are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group.

Abstract: The present invention relates to arylated camphenes, processes for their preparation and uses thereof for the manufacture of medicaments for the treatment of diseases, disorders or conditions associated with, or benefiting from stimulation of CB2 receptors.

Abstract: The present invention relates to a cyclization process of forming a multiple ring compound from an isoprenoid compound. The cyclization process involves reacting the isoprenoid compound with an acetal initiator under conditions sufficient to form the multiple ring compound. The isoprenoid compound is contacted with an initiator an optionally with a catalyst. Cyclization occurs by reaction of the initiator with the isoprenoid compound. Cyclic acetal compounds wherein the acetal forms part of 6-membered unsaturated ring are also defined.

Abstract: A photochromic chromene compound having an indeno(2,1-f)naphtho(1,2-b)pyran structure as its basic skeleton, an aryl group or a heteroaryl group at the 6-position carbon atom of the structure and an electron donor group having a Hammett constant ?p of not more than ?0.1 at the 7-position carbon atom.

Abstract: The present invention relates to a method of making indeno-fused naphthol materials, that involves, with some embodiments, forming an indanone acid intermediate, which can be represented by the following general Formula V, With Formula V, m is from 0 to 4, and R1 for each m, Rg and Rh can each be independently selected from, for example, hydrogen and hydrocarbyl. The present invention also relates to a method of making an indeno-fused naphthopyran that involves an indanone acid intermediate synthetic route.

Abstract: The present invention relates to methods of making fused ring compounds, such as indeno-fused naphthols, and fused ring indenopyran compounds, such as indeno-fused naphthopyrans, that each employ an unsaturated compound represented by the following Formula II. Referring to the unsaturated compound of Formula II: Ring-A can be selected from optionally substituted aryl (e.g., phenyl); m can be, for example, from 0 to 4; R1 for each m can be selected from optionally substituted hydrocarbyl (e.g., C1-C6 alkyl) optionally interrupted with at least one linking group (e.g., —O—); and R3 and R16 can each be independently selected from, for example, hydrogen or optionally substituted hydrocarbyl, such as C1-C8 alkyl. When Ring-A is a phenyl group, the unsaturated compound represented by Formula II can be referred to as an unsaturated indanone acid/ester compound, or an indenone acid/ester compound (depending on whether R16 is hydrogen, or an optionally substituted hydrocarbyl group).

Abstract: A compound represented by the formula (1) is provided. In the formula (1), for example, R1 and R2 are alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 2 to 10 carbons; the ring A and the ring B are 1,4-cyclohexylene or 1,4-phenylene; Z1 and Z2 are a single bond and Z3 is —CH2O— or —OCH2—; Y1 and Y2 are halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2 or —OCH2F; and m and n is 0, 1 or 2, p is 1 or 2, and the sum of m, n and p is 1, 2 or 3.

Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.

Abstract: The present invention relates to compounds represented by the following Formulas (I) and (II), Ring-A of Formulas I and II can be, for example, an aryl group, and Q? and Q?? can each be independently selected from groups, such as, halogen, —OH, —CN, amine groups, amide groups, carboxylic acid ester groups, carboxylic acid groups, alkenyl groups, alkynyl groups, carbonate groups, sulfide groups, and sulfonic acid ester groups. The present invention also relates to photochromic compositions and photochromic articles that include one or more photochromic compounds, such as represented by Formula II.

Abstract: The present invention relates to 4,4?-substituted spirobifluorenes which are suitable, owing to excellent properties, as functional materials in organic electroluminescent devices. In addition, the present invention relates to a process for the preparation of 4,4?-substituted spirobifluorenes and to the use of these compounds in organic electroluminescent devices.

Abstract: An object of the present invention is to provide (i) a novel non-crystalline form of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene, which non-crystalline form maintains quality at a certain level, and is excellent as a polymer material, and (ii) a method of preparing the non-crystalline form. According to the present invention, molten 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene in a liquid form is cooled and therefore is solidified. With the method, it is possible to provide a novel non-crystalline form of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene which has a small risk that powder dust of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene might cause explosion or a health problem. Further, the non-crystalline form of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene can be adjusted arbitrarily in particle diameter by, for example, pulverizing the non-crystalline form in accordance with equipment or usage.

Abstract: Disclosed are new semiconductor materials prepared from polycyclic aromatic compounds. Such compounds can exhibit high carrier mobility and/or good current modulation characteristics. In addition, the compounds of the present teachings can possess certain processing advantages such as solution-processability and/or good stability at ambient conditions.

Abstract: [Summary] [Problem] Provision of a novel compound which is easily-soluble in isopropyl acetate superior in liquid-separation operability, and can be used for a production method of peptide and the like, that provides a final product simply by extraction-layer-separating, without crystallization and isolation of each intermediate in each step. [Solving Means] It has been found that the above-mentioned problems can be solved by a particular branched chain-containing aromatic compound.

Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.

Abstract: The present invention provides a liquid crystal display device producing less image sticking. The liquid crystal display device of the present invention comprises: a pair of substrates; and a liquid crystal layer between the substrates, wherein at least one of the substrates comprises an alignment film and a photopolymer film on the alignment film, the photopolymer film comprises polymers constituted by a photopolymerizable monomer, the photopolymerizable monomer includes two or more polymerizable functional groups, the polymerizable functional groups are bonded to each other through two or more aromatic rings, the aromatic rings include at least one naphthalene ring, and a bond between the naphthalene ring and another aromatic ring has a rotational degree of freedom.

Abstract: A method for producing a fluorene derivative by reacting fluorenone with a phenol or a phenoxyalcohol in the presence of an acid catalyst includes: adding an alkali to an obtained reaction liquid containing a fluorene derivative; and concentrating a resultant mixture liquid without removing the alkali thus added and a reaction product of the alkali, thereby separating an unreacted phenol or unreacted phenoxyalcohol.

Abstract: A method of producing a crystal polymorph of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene, comprising the steps of reacting fluorenone and 2-phenoxyethanol in the presence of a heteropolyacid, initiating deposition of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene at lower than 50° C. from the resultant mixture to obtain a crude product of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene, dissolving the crude product in at least one solvent selected from the group consisting of aromatic hydrocarbon solvents, ketone solvents and ester solvents, and initiating deposition of 9,9-bis(4-(2-hydroxyethoxy)phenyl)fluorene at 50° C. or higher.

Abstract: The present invention relates to novel tetralin ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.

Abstract: A naphthalene derivative having formula (1) is provided wherein cyclic structures Ar1 and Ar2 denote a benzene or naphthalene ring, X is a single bond or C1-C10 alkylene, m is 0 or 1, and n is such a natural number as to provide a molecular weight of up to 100,000. A material comprising the naphthalene derivative or a polymer comprising the naphthalene derivative is spin coated to form a resist bottom layer having improved properties. A pattern forming process in which a resist bottom layer formed by spin coating is combined with an inorganic hard mask formed by CVD is available.

Abstract: 1,4 fullerene deriatives useful for solar cells are provided, where their structures allow for straightforward functionalizations to tune their properties in terms of solubility and LUMO energy levels.

Abstract: A catalyst for olefin polymerization and method of preparing the same are disclosed.

Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer.

Abstract: A diol from which a resin material having high processability and a high refractive index can be manufactured, a polycarbonate resin and a polyester resin which is a polymer of the diol, and a molded article and an optical element formed of the polymer. The diol is represented by the general formula (1) shown below; the polycarbonate resin and the polyester resin are polymers thereof; and the molded article and the optical element are formed of the polymers, wherein R1 and R2 each independently denote one of a hydrogen atom and an alkyl group having 1 or more and 6 or less carbon atoms; Q denotes one of an oxyethylene group, a thioethylene group and a single bond.

Abstract: Provided are compositions including (3R, 4R, 6R)-stereoisomers of phenyl substituted pinenes having CB receptor agonist properties, methods of treating diseases or disorders with the pharmaceutical compositions, and processes for their preparation are also provided.

Abstract: The present invention provides the use of pelorol analogs of Formula, (I) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.

Abstract: A photosensitive compound whose size is smaller than conventional polymer for photoresist, and which has well-defined (uniform) structure, and a photoresist composition including the same are disclosed. The photosensitive compound represented by the following formula. Also, the present invention provides a photoresist composition comprising 1 to 85 wt % (weight %) of the photosensitive compound; 0.05 to 15 weight parts of a photo-acid generator with respect to 100 weight parts of the photosensitive compound; and 10 to 5000 weight parts of an organic solvent. In the formula, n is 0 or 1, x is 1, 2, 3, 4 or 5, y is 2, 3, 4, 5 or 6, z is 0, 1, 2, 3 or 4, R, R? and R? are independently hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms, and R?? is a hydrogen atom or hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms.

Abstract: An organic compound is represented by general formula (1): where R1 to R18 are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group.

Abstract: A compound for an organic thin film transistor having a structure represented by the following formula (1): wherein R1 and R2, and R3 and R4 are respectively combined with each other to form an aromatic hydrocarbon ring having 6 to 60 carbon atoms or an aromatic heterocyclic ring having 3 to 60 carbon atoms; the ring being fused to the ring to which the groups are bonded, whereby the structure of the formula (1) has 5 or more aromatic rings that are fused; and the fused rings formed by R1 and R2, and R3 and R4 each may have a substituent.

Abstract: The invention relates to the use, or methods (especially with regard to animals, especially human, that are in need of such treatment) comprising the use, of an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from the group consisting of Schisandra, Illicium, Kadsura, Steganotaenia and Magnolia, alone or as supplement, as active ingredient in the regulation of body weight and/or fat loss and/or for the management of obesity, either in humans or in animals, to the use of said extract and/or natural compound(s) or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation for the regulation of body weight and/or fat loss and/or for the management of obesity either in humans or in animals. The above extract and/or compound(s) can further be used to reduce one or more adverse metabolic parameters in a subject.